BRÈVE

sur Theralase Technologies Inc. (isin : CA88337V1004)

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Theralase Technologies Inc. has announced significant preclinical findings showing that its lead drug formulation, Ruvidar(TM), is more effective than Acyclovir in targeting the Herpes Simplex Virus 1 (HSV-1). This finding positions Ruvidar(TM) as a potent alternative to traditional antiviral treatments.

The studies conducted at the University of Manitoba demonstrate that Ruvidar(TM) not only outperforms Acyclovir in inhibiting virus replication but is also effective when administered after infection. This improves upon Acyclovir, which fails to prevent HSV-1 replication if added one day post-infection. Notably, Ruvidar(TM) reduced HSV-1 replication by 10 million-fold under these conditions.

Theralase’s CEO, Roger DuMoulin-White, states that the company is now seeking partnerships or licensing opportunities to advance Ruvidar(TM) for both topical and oral treatments targeting herpes simplex.

These findings underscore Ruvidar(TM)'s potential in the antiviral drugs market, projected to reach USD 71.1 billion by 2032, and offer new avenues for prophylactic and treatment applications.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Theralase Technologies Inc.